Polyoxidonium - compositium pro formum medicinalium et vaccinum Uses, Dosage, Side Effects and more
Polyoxidonium - compositium pro formum medicinalium et vaccinum is under investigation in clinical trial NCT04381377 (Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19).
| Attribute | Details |
|---|---|
| Trade Name | Polyoxidonium - compositium pro formum medicinalium et vaccinum |
| Generic | Azoximer bromide |
| Azoximer bromide Other Names | Azoximer bromide, Poly((1-(carboxymethyl)piperazin-1-ium-1,4-diyl bromide)ethylene-co-((piperazin-1,4-diyl 1-oxide)ethylene) |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Russia |
| Last Updated: | January 7, 2025 at 1:49 am |
